Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473960 | 1.00 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL29370580 | 1.00 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22291363 | 1.00 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27037582 | 1.00 | L3MBTL1 (0.40) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL14448316 | 0.80 | NNMT (0.56) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5474478 | 0.80 | NNMT (0.56) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL5474481 | 0.80 | NNMT (0.56) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22291573 | 0.79 | POLB (0.44) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL22291571 | 0.79 | POLB (0.44) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL31512043 | 0.78 | ALDH1A1 (0.43) | L3MBTL1HTTALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096651-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250085300-A1 | STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS | FOGHORN THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| US-20240325370-A1 | THERAPEUTIC REGIMENS OF A DEGRADER OF BRD9 | FOGHORN THERAPEUTICS INC. | 2024-10-03 | — | — | US | disclosed |
| CN-115052594-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240190894-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | FOGHORN THERAPEUTICS INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240166668-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-05-09 | — | — | US | disclosed |
| US-11851445-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11787800-B2 | BRD9 degraders and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022025880-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| CN-113874016-A | Compound and use thereof | 福宏治疗公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3917526-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2021155225-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155225-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210230190-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-07-29 | — | — | US | disclosed |
| US-20210230190-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250085300-A1 | STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS | GCDH, GLRX3, GRHPR | L3MBTL1 4395/4885HTT 2902/4885ALDH1A1 382/4885 |
| US-20220048906-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | L3MBTL1 769/4885HTT 377/4885ALDH1A1 1387/4885 |
| US-20240190894-A1 | CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME | CS, SMARCC2, SMARCC1 | L3MBTL1 4679/4885HTT 2171/4885ALDH1A1 3171/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | L3MBTL1 769/4885HTT 377/4885ALDH1A1 1387/4885 |
| US-20240166668-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | L3MBTL1 1010/4885HTT 234/4885ALDH1A1 2571/4885 |
| US-20240150348-A1 | BRD9 DEGRADERS AND USES THEREOF | BRD9, BRWD1, BRD2 | L3MBTL1 1443/4885HTT 666/4885ALDH1A1 3268/4885 |
| US-11851445-B2 | Compounds and uses thereof | VHL, CLN6, TFEB | L3MBTL1 1010/4885HTT 234/4885ALDH1A1 2571/4885 |
| US-20210230190-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | L3MBTL1 1010/4885HTT 234/4885ALDH1A1 2571/4885 |
| US-20240325370-A1 | THERAPEUTIC REGIMENS OF A DEGRADER OF BRD9 | BRD9, SND1, SBDS | L3MBTL1 1010/4885HTT 1261/4885ALDH1A1 4188/4885 |
| US-11787800-B2 | BRD9 degraders and uses thereof | BRD9, BRWD1, BRD2 | L3MBTL1 1443/4885HTT 666/4885ALDH1A1 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.